Medicus Pharma Ltd.

Medicus Pharma Ltd. is a clinical-stage biotech company focused on developing and advancing novel therapeutic assets, with a current emphasis on skin cancer programs delivered through dissolvable microneedle arrays. It also pursues opportunistic acquisitions and partnerships to broaden its pipeline, including the acquisition of Antev Limited and its Teverelix program.

1.00

1.00

— Medicus Pharma Ltd.
%
Skin cancer therapeutics70% Investigational non-invasive treatments for basal cell carcinoma and squamous cell carcinoma using D-MNA technology.
Drug delivery platform15% Patent-protected dissolvable microneedle array technology used to deliver doxorubicin locally.
Pipeline acquisition and development10% Acquired and partnered clinical assets such as Teverelix that expand the oncology/urology pipeline.
Veterinary therapeutics5% Development of D-MNA-based treatment for external squamous cell carcinoma in horses.

Medicus does not yet sell commercial products; its current customers are clinical trial sites, investigators, CROs, and...

  • Clinical trial sites and investigatorsprimary

    Hospitals and investigators run the BCC studies and generate the clinical data needed for approval.

  • Regulatorsprimary

    FDA and UAE DOH review study plans, safety data, and development pathways that determine whether programs can advance.

  • CROs and research partnerssecondary

    Contract research organizations coordinate trial operations, site management, and data collection.

  • Future oncology prescribersemerging

    Dermatologists, oncologists, and specialty clinics would buy approved skin cancer therapies if commercialization occurs.

  • Veterinary oncology usersemerging

    Veterinarians treating equine SCC would be the end users for the horse indication if approved.

The company is headquartered in the United States and its current development activity is centered there, with...

  • •United States is the core operating base and main trial market
  • •U.S. sites host the SKNJCT-003 Phase 2 study
  • •Europe is being added as an expansion region for clinical trials
  • •UAE hosts SKNJCT-004 with local hospitals and a UAE CRO
  • •UK exposure increases through the Antev Limited acquisition

Medicus is building a clinical-stage pipeline around its D-MNA platform while expanding the number of indications and...

01
Complete and expand skin cancer clinical trialsshort-term

Clinical proof-of-concept is the main value driver for the D-MNA platform and future approvals.

02
Broaden the pipeline through acquisitionmedium-term

Additional assets reduce dependence on a single program and create more shots on goal.

03
Secure financing for R&D executionshort-term

The company has no product revenue and must fund trials through equity or non-dilutive sources.

The company is exposed to classic clinical-stage biotech risks: trial failure, regulatory setbacks, and the need for...

critical

Financing risk

The company currently has no operating revenue and must fund R&D through equity or other sources.

Scope
Ongoing trial and corporate spend
Materiality
high
high

Clinical trial failure for D-MNA programs

The company’s value depends on positive efficacy and safety results from SKNJCT studies.

Scope
SKNJCT-003 and SKNJCT-004
Materiality
high
high

Regulatory delay or non-approval

Advancement to later-stage development and commercialization requires FDA and local approvals.

Scope
FDA, UAE DOH
Materiality
high
medium

Acquisition integration risk

Antev may be difficult to integrate and Teverelix may not develop as expected.

Scope
Antev Limited acquisition
Materiality
medium
medium

Operational complexity across geographies

Multi-country trials require coordination across hospitals, CROs, and regulators.

Scope
U.S., Europe, UAE
Materiality
medium
Research and development expense recognition
Reported losses rise as SKNJCT and acquisition-related development spend increases
Going-concern assessment
Material for liquidity and solvency analysis
Stock-based compensation valuation
Can materially affect operating loss in a small-cap biotech
Financing instruments
Affects dilution, interest/other finance income or expense, and equity balances

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

PMV Pharmaceuticals, Inc.

PMVP · Pharmaceutical Preparations

MEDICINOVA INC

MNOV · Pharmaceutical Preparations

Medivir

MVIR.ST · Health Care

: 28/04/2026